Original ResearchPublished 7 September 2026Bridging to systemic therapy: PSMA-PET-based early and repetitive stereotactic body radiotherapy for nodal and bone oligo-recurrent prostate cancerArne Grün · Alexandra Partyka · Markus Galler · Torsten Schlomm · Dirk Böhmer · Kurt Miller · Daniel Zips · Goda KalinauskaiteFrontiers in Urologydoi 10.3389/fruro.2026.1738508
Original ResearchPublished 29 July 2026MRI-derived T stage predicts nodal positivity on PSMA PET/CT in high-risk primary prostate cancerMichael Courtney · Robert Whiriskey · Ciaran Johnston · Niall SheehyFrontiers in Nuclear Medicinedoi 10.3389/fnume.2026.1854064
ReviewPublished 15 July 2026PSMA-targeted radioligand therapy in advanced prostate cancer: a narrative review of ^177Lu-PSMA, emerging ^225Ac-PSMA strategies, and therapeutic sequencingNatalia Gierulska · Nina Jankowska · Adrianna Kwiatkowska · Piotr Kuchno · Kinga Łysak · Katarzyna Szklener · Kamil Kośmider · Magdalena SkórzewskaOncology Reviewsdoi 10.3389/or.2026.1834484
ReviewPublished 29 May 2026Next-generation imaging in prostate cancerAhmed Rabie · Maurizio Buscarini · Osama ZaytounFrontiers in Urologydoi 10.3389/fruro.2026.1829407
Case ReportPublished 10 March 2026Incidental detection of PDAC via 18 F-PSMA PET/CT in a patient with recurrent prostate cancer. A case reportGiordano Savelli · Mattia Bonacina · Alberto Soffientini · Elvira Archiati · Claudio Bnà · Alberto ZaniboniFrontiers in Nuclear Medicinedoi 10.3389/fnume.2026.1767321
